. Characterisation of the anti-RGMa antibody 5F9. Related to Figure 
A C B Supplemental Experimental Procedures
Antibody generation and humanization The rat anti-RGMa mAb 5F9 (r5F9) was generated by hybridoma technology. Briefly, Harlan Sprague Dawley female rats were immunized subcutaneously with recombinant human RGMa (R&D Systems, cat# 2459-RM-050) in complete Freund's adjuvant. Spleen cells from immunized rats were fused with SP2/0 myeloma fusion partner using standard techniques. Hybridomas were screened by direct ELISA for binding to human RGMa and fluorescence-activated cell sorting (FACS) analysis for binding to RGMa-expressing HEK293 stable cell line. Positive hybridoma cell lines were subcloned by limiting dilution. r5F9 is the hybridoma lead after subcloning.
The rat 5F9 mAb was humanized to reduce the potential immunogenicity by engineering the rat mAb to be highly similar to an antibody naturally expressed in humans. The humanization method employed is complementarity determining regions (CDR) grafting in which the CDRs of a non-human antibody are grafted into the human frameworks. Suitable human germlines for humanization are identified by homology studies and are chosen as acceptors for CDR grafting. CDR regions are then grafted into the human frameworks and engineered antibodies are generated and characterized in in vitro binding and functional assays. The antibody that retains the binding and functional activities is chosen as the lead humanized antibody. h5F9 is the lead humanized mAb of r5F9.
Cell culture, immunostaining and Western blotting Cell culture experiments were described elsewhere (Schaffar et al. 2008) . Briefly, human SH-SY5Y cells were cultivated in Earle's balanced salt solution/F12 (EBSS/F12) medium supplemented with 10% fetal bovine serum (FBS) and 1% non-essential amino acids. For induction of neurite outgrowth cells were cultured in medium supplemented with 10 µM retinoic acid (RA). Human Ntera2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) medium supplemented with 10% FBS and 5% horse serum. For neuronal differentiation, Ntera2 cells were seeded at a density of 2.5 10 6 cells/175 cm 2 in differentiation medium (DMEM medium supplemented with 10 µM RA) for 3 weeks. Differentiated neuronal Ntera2 cells were separated from other cells by tapping and seeded on poly-L-lysine and laminin coated plates (100 µg/mL and 20 µg/mL, respectively (both Sigma-Aldrich)) in neurobasal medium supplemented with B27 and glutamine. HEK293 cells stably expressing RGMa were cultured in DMEM supplemented with 10% FBS. For immunofluorescence analysis, cells were fixed in 2% paraformaldehyde (PFA) over night at 4°C. Permeabilization and blocking was done with PBS containing 0.1% Triton X-100 and 3% bovine serum albumin (BSA) (30 min at room temperature (RT)). Subsequently, cells were incubated with the indicated primary and eventually secondary antibodies in PBS/T/BSA (PBS with 0.1% BSA, 0.05% Tween-20) for 1 h each. Before and after each antibody treatment cells were washed three times with antibody dilution buffer. Nuclei were counterstained using bisbenzimide (H33258) and embedded in Flouromount-G mounting medium (#0100-01, Southern Biotech). Cells were analyzed using a high content microscope to guarantee same settings for every well (ArrayScan XTI High Content Analyser, Thermo Scientific). Cell staining was performed with AlexaFlour-488 Phalloidin staining (#A12379; Invitrogen). Neurite outgrowth index was calculated by subtraction of nucleus staining from cell staining divided by nucleus staining. HEK293 cells were lysed with RIPA buffer (#89900, Thermo Scientific) according manufactures protocol and proteins separated on Polyacrylamid gel system Criterion TGX (#567-1095, Biorad) and transferred with Trans-Blot Turbo MIDI PVDF (#170-4157, Biorad). PVDF membrane was blocked over night with 3 %BSA in PBS/T. First antibody incubation was done in 3% milk powder for 2 hours at RT, followed by 3 x washing with PBS/T/BSA. Secondary stain was done with ABC Staining kit (#32050, Thermo Scientific) in the case of primary anti-RGMa antibody BAF2459 (R&D) and with anti-human HRP (Clone JDC-10, Southern Biotech) in the case of humanized antibodies. All blots were developed with ECL substrate SuperSignal West Femto (#34095, Thermo Scientific) and exposed for 2 and 10 seconds, respectively. For growth analysis of differentiated SHSY5Y on different coated surfaces, stripes were prepared as described previously (Rajagopalan et al. 2004 ) using poly-L-lysine/laminin coated glass slides and 25 µg/mL RGMa. For neurite outgrowth analysis, cells were stained with beta-III tubulin antibodies. Cell area was measured and analysed using the AxioVision software (Zeiss) and put in ratio to the stripes to be able to calculate the preferred area of growth. To investigate migration of differentiated SH-SY5Y cells a Multiwell Insert System was used. 600 µl Medium with 500 µg/ml epidermal growth factor (#11376454001, Roche) was given into each well of a 24 well Boyden Chamber (#351185, BD Falcon) and the insert put back in. Subsequently 1 x 10 5 cells were plated with 500 µl medium together with substances for investigation in the upper chamber. The upper and lower chambers were only separated by a membrane with a pore size of 8 µm. After 24 hours cells were fixed with 2% PFA for 2 hours and the upper part of the membrane cleaned twice with cotton swaps. Cells were stained as described above with beta tubulin and analyzed using the AxioVision software (Zeiss).
Lipid raft fraction Isolation of different lipid density fractions was described elsewhere in great detail (Tassew et al, 2014) .
Rat optic nerve crush model Experiments were carried out in adult male Wistar rats obtained from Charles River (D) Laboratories (Germany). The animals were kept in single cages on a 12:12 hour light/dark cycle with food and water ad libitum. The optic nerve crush was performed always only at the left eye by minimal anterior surgery as described before (Monnier et al, 2011) . Before and during the operation, the procedure animals were anesthetized by inhalation anaesthesia using Sevoflurane (2-3%, 0.8-1.0 L/min oxygen flow rate) (Abbott GmbH Co. & KG, Delkenheim, Germany) and fixed on the operation table by using jaw clamp and adhesive tape for the limbs. A drop in body temperature was prevented by mounting animals on a heating pad. For anterior crush surgery of the rat optic nerve, the 1% Lidocaine solution was used to anesthetize the cornea of the left eye. As a first step, a microsurgical cut (2-3 mm) of the adjacent tissue in the outer corner of the eye was performed. As a next step, the optic nerve was exposed by using a pair of forceps to move to the side the eye muscles and lacrimal gland, thus sparing it. As a further step, the meninges were longitudinally opened by using microscissors to expose the optic nerve. This results in a higher mobility of the eye and enables lateral rotation of the eye and access to its left optic nerve. The optic nerve was injured approximately 1-3 mm behind the eye, using a pair of forceps set to provide a fixed maximum pressure for 10-20 seconds. Special care was taken not to damage the vascular supply to the eye. After minimal invasive surgery, the animals were placed on paper towels in the clean cage placed on the warmer to control the body temperature until they started to move. An ointment which contains antibiotic (Gentamytrex, Dr. Mann Pharma, Germany) was applied onto the eye to avoid bacterial infection and drying-out of the sclera. Carprofen (Rimadyl, 5 mg/kg) was applied subcutaneously for postoperative pain therapy directly after surgery and then once per day for a 3 day period. The animals were observed and controlled regularly several hours directly after surgery and in the next 2-4 days to make sure that all the animals survived and recovered from anesthesia and surgery. The above described modified anterior optic nerve crush approach has significant advantages in comparison with the standard optic nerve crush procedure which originates from the posterior part of the eye. Specifically, in the procedure described herein, no large open wounds are generated which require suturing and the infection risk of the very small wounds is significantly reduced. In addition, as a result of the shorter time required for the crush (the above described anterior method is approximately 3 times faster than the posterior method known in the art) animals suffer less and are thus less stressed. Moreover, the amount of pain suffered by the animals is significantly reduced and animals recover at much higher rates and much more quickly.
Systemic administration of antibodies For systemic antibody delivery, male Wistar rats were treated systemically intravenously, (i.v.) with a rat or humanised 5F9 antibodies, or with the corresponding isotype control antibodies (p21 or hIgG). Rats were injected once per week intravenously with different doses of antibody (between 0.1 and 10 mg/kg of antibody) and injections were started immediately after optic nerve crush. All rats received 5 injections and in most experiments rats were euthanized 6 weeks after crush injury. Experimenters were blinded and tissue isolation, processing, preparation of sections and quantitative analysis was done as described before (Monnier et al, 2 011; Koeberle et al, 2010) . Composite images of rat optic nerves were prepared, the crush site was identified and GAP-43 positive fibers extending beyond the crush site for 500 -1500 µm were counted.
Measurement of Retinal Nerve Fibers in Retina Explants
In order to observe protection of retinal nerve fiber layer (RNFL) degeneration, a new laboratory assay method was used. This method is based on explanting and analyzing adult rat retina from the eyes of rats with optic nerve crush and systemically treated with antibody 5F9, vehicle or isotype control antibodies. Animals were deep anesthetized with Sevoflurane (8%; Abbott GmbH Co. & KG, Delkenheim, Germany), then immediately sacrificed by opening the ribcage and perfused with 4% PFA solution through the left heart ventricle. The eyes were dissected with the connective tissue adjusted and placed in 4% PFA until preparation of retina takes place. The preparation of the retina was performed in Hank's Balanced Salt Solution (HBSS, Magnesium-and Calcium-free; Life Technologies GmbH, Darmstadt, Germany). The eye was fixed at the connective tissue by tweezers and a round cut was made in sclera just around the cornea in order to remove the retina. Thereafter, the retina was placed in 10% neutral phosphate-buffered formaldehyde solution (pH 7.3, Fisher Scientific GmbH, Schwerte, Germany) at +4°C until immunofluorescent staining was performed according to the protocol described below. The retina preparation was washed with TBS, followed by blocking and permeabilization with 5 % BSA, 1 % Triton X-100 in TBS for 30 minutes and then washed again with TBS. Primary antibodies, namely, monoclonal Ab TUJ-1, a mouse anti-ß III Tubulin Ab (AbCam, Cambridge, UK), in TBS, 5 % BSA, was added for 1 hour at room temperature in the dark followed by washing with TBS, 0.1 % Tween 20. Next, a secondary antibody, Donkey anti-mouse Cy3 (Jackson ImmunoResearch (Dianova GmbH) Hamburg, Germany), and Bisbenzimid (50 µg/ml, 1:100 dilution in TBS, 5 % BSA) were added for 1 hour at room temperature in the dark followed by washing with TBS, 0.1 % Tween 20, and the subsequent washing with desalted H 2 O. The half sphere of the retina was then cut in four points and transferred into a drop of the embedding medium Fluoromount G, spread flat with a cover glass and stored at +4°C in the dark. Quantitative analysis of the protective effect of RGMa antibodies on the (RNFL) in the eye was done using the Axiovision software, randomly selected images (n = 12) of each retina were chosen and the number of nerve fibers determined for each image. Alternatively composite images of the retina were prepared and all fiber bundles converging to the optic nerve head were counted. For these experiments, 5 -8 retinas with crushed optic nerves were used for each group. Data analysis and statistical analysis was performed using the GraphPad prism program.
Testing of RGMa antibodies in a focal spinal Experimental Autoimmune Encephalomyelitis Model
Kerschensteiner et al. (Kerscheinsteiner & et al, 2004 ) developed a focal, localized experimental autoimmune encephalomyelitis (EAE) model where large inflammatory lesions are not spread randomly in spinal cord, brain and optic nerve, but can be selectively induced in either in the spinal cord or other brain areas. Using this focal or targeted EAE model, large inflammatory lesions, very similar to MS spinal cord lesions, are induced in the dorsal columns of the spinal cord, affecting the corticospinal tract. In this model, adult female Lewis rats are first immunized with the myelin oligodendrocyte glycoprotein (MOG). Three weeks after immunization, MOG antibody titers were determined and animals with a positive immune response were injected with a cytokine mixture (TNFα 1000 ng, IFNg 150 U) locally at thoracic level 8 (T8). Within one week after cytokine injection, the rats developed hind limb motor defects, tail paralysis and gait disturbances reaching an EAE score of 2.5. Four weeks after cytokine injection, the score improved to 1.0 (Kerscheinsteiner & et al, 2004) . Due to the higher amount of TNFα used in our models and the higher concentration of MOG used for MOG antibody generation, control vehicle treated rats took 6-7 weeks to improve to an EAE score of 1.0 -the plateau phase was therefore significantly extended in comparison to the original model. Female Lewis rats have been injected subcutaneously with 75 µl of MOG (75 µg, 1-125 aa, BlueSky Biotech, Worcester, MA) dissolved in saline and then emulsified with 75 µl of Incomplete Freund's Adjuvant (IFA, Sigma-Aldrich Chemie GmbH, Munich, Germany). Two to three weeks after MOG immunization, blood samples were analyzed with an ELISA assay to detect MOG-specific antibodies. Immunization resulted in induction of MOG antibodies in more than 90% of immunized rats. In this strain however, MOG antibody induction did not result in any disease symptoms. Lewis rats only developed motor deficits after local injection of 2 inflammatory cytokines (TNF α, IFNg) into the thoracic spinal cord at thoracic level 8 (T8). For cytokine injection, rats were subject to inhalation anesthesia with Sevoflurane (2-3%, 0.8-1.0 L/min oxygen flow rate; Abbott GmbH Co. & KG, Delkenheim, Germany) and a laminectomy was performed by a specially adapted procedure, which is faster and less invasive than the standard surgery. Specifically, the skin on the back of the rat was shaved and disinfected with Betadine® solution and a 2-3 cm cut was made with scalpel starting approx. from T3-4 till T11-12. The superficial fat was separated with fine scissors from the muscles and the muscles were cut by the middle line along the spine from one side. The gap between T8 and T9 was located and T8 was cleared from adjacent tissue. A microdrill was used to make a round hole approximately 1-2 mm in diameter in T8 and small tipped forceps were used to remove the periosteum and any bone fragments. Next, the dura mater was removed with micro scissors and a stereotactic injection was done by a very thin glass capillary. Briefly, the capillary was connected to a 10 µl Hamilton syringe with Luer Tip (LT) and filled with mineral oil (Sigma Aldrich) to avoid any air in the closed injection system. Using an automatic injector, the capillary was filled with the cytokine mixture in PBS or just PBS with traces of Evans blue pigment to visualize the solution in the capillary. A four times higher dose of TNFα (1000 ng) and the same dose of IFNγ (150 U) was used as reported by Kerschensteiner et al. (Kerscheinsteiner & et al, 2004) The four times higher dose resulted in a significant extension of the recovery process in vehicle or control treated rats. In the next step, a glass capillary was inserted to a depth of 1 mm and 2 µl of the cytokine mixture were injected in the middle of spinal cord at T8 during a 5 minute-period using an automatic injector. After applying disinfection solution and closing the wound, rats were treated with an analgesic drug Rimadyl (5 mg/kg, directly after surgery and daily for another 3-4 days). Rats were then placed in a clean page on paper towels and were kept in the warmth until they awoke. Rats developed first symptoms within one week after cytokine injection, at which point the antibody treatment was started. An hIgG (directed against hIL-18, not cross-reactive with rat IL-18 or a rat p21 isotype control antibody and several different RGMa antibodies (humanised 5F9, rat 5F9) were used and rats were treated once per week via the intravenous route. EAE scoring was done daily and scores were documented. Individuals conducting the experiments were blinded for the different treatment groups. After a period of 27 -29 days post cytokine administration, the animals were sacrificed; spinal cords were dissected and post-fixed in 4% PFA at 4 degrees Celsius (°C) overnight. Tissues were transferred to 30% sucrose at 4°C for another 1 or 2 days. After the cryoprotection, tissues were embedded in tissue freezing medium and frozen at -20°C, sagittal cut by cryostat in 20 µm sections. Sections were fixed in Aceton at -20°C for 10 minutes, washed 3 times in TBS and blocked by 5% BSA, 1% Triton X-100 in TBS for 30 min. After washing twice with TBS, sections were incubated with primary antibodies as listed in the Table for 1 hour at room temperature. Sections were then washed 3 times in TBS with 0.1% Tween 20, incubated with secondary antibodies (Table) and Bisbenzimide (50 µg/ml, 1:100 dilutions). Finally, sections were washed twice in TBS with 0.1% Tween 20 and 1 time in TBS, and covered by coverslips with Fluoromount G.
Spinal cord sections were observed using a fluorescent microscope (Axiovert 200M, Carl Zeiss Microscopy GmbH, Germany) . The inflammatory lesion was determined in the optic nerve using anti-CD68, a clinically highly relevant marker for activated microglial cells and macrophages. Within this inflammatory lesion, the area of expression of the following proteins was measured with imaging analysis software (Axiovision 4.7): GAP-43 (regeneration marker), and MBP (myelin basic protein, a marker for remyelination or preserved myelin tracts). To determine the CST lesion, the biotinylated dextran amine (BDA) anterograde tracing was performed two weeks after cytokine injection. Rats were injected with 0.9 µl of a 10% solution of BDA (10,000 in phosphate buffer, pH7.4) into the hind limb area of the motor cortex at the coordinates: 2 mm posterior, 2 mm lateral, and 1.5 mm dorsal in relation to bregma. Two weeks after BDA tracing, rats were euthanized by 4% PFA cardiac perfusion and spinal cord were dissected and sectioned as described above. The Streptavidin Alexa Fluor® 568 (Invitrogen, S11226) was used to visualize the labeled CST fibers.
Testing of RGMa antibodies in a focal Optic Nerve Inflammatory Model In order to confirm the positive effect of RGMa antibodies and to better recapitulate the optic neuritis commonly observed in MS patients, we adapted the focal spinal EAE model described above to induce cytokine-mediated lesions in the optic nerve. The adult female Lewis rats were sensitized with MOG according to the protocol described above and the titer of the produced antibody against MOG was determined two weeks after. However, the injection of cytokine solution by a glass capillary is not possible in this model, due to the much lower accessibility of the injection site and relatively big volume of the cytokine solution compared the nerve width. Therefore, the cytokine mixture of TNFα (250 ng) and INFγ (150U) was applied in the Gelfoam® locally onto the optic nerve that was exposed as described for the Optic Nerve Crush model. Since the procedure is also minimally invasive, it requires only minimum of post-surgical care of the animals with daily treatment with Rimadyl (5 mg/kg) for 3 days after the surgery. Directly after the surgery, the animals were systemically treated with the RGMa antibodies by the protocol identical for the Optic Nerve Crush model in order to directly compare the outcome. After 4 weeks of the systemic antibody application animals were sacrificed and the optic nerves and retinas were isolated and processed as described above for the immunohistological analysis of neuroregeneration and to measure the retinal nerve fiber layer. Additionally, to visualize the cytokine-induced lesions, the optic nerves were stained for the macrophage marker CD68 that would identify the inflammation site.
RGMa immunostaining of MS autopsy sections
Immunohistochemical staining of brains from MS patients was performed as previously described (Rus & et al, 2005) . The air-dried cryostat brain sections (4-6 μm) were fixed for 10 min in acetone containing 0.3% H 2 O 2 to remove endogenous peroxidase. Tissue sections were blocked for 10 min with 2.5% horse serum, then incubated overnight at +4°C with goat anti-RGMa antibody (R&D Systems, Minneapolis, MN). The slides were washed three times for 3 min with PBS, pH 7.4, and then incubated with biotinylated anti-goat IgG secondary antibody followed by streptavin/peroxidase complex (Vector Labs, Burlingame, CA). The specific reaction was developed using NovaRED (Vector Labs, Burlingame, CA) as a substrate; slides were then counterstained with Harris's hematoxylin (Sigma, St. Louis, MO) and mounted with permanent mount.
Treatment of progressive MS patients with TCA The study included 14 chronic progressive MS patients (5 PPMS and 9 SPMS patients: 6 men and 8 women; age: 49  3 years [mean  SEM]; EDSS-score at baseline: 5.07  0.43). TCA treatment was continued up to six TCA applications (40 mg) in most of the participants. They did not suffer from an acute onset of exacerbation or a recent clearly increased progression of their symptoms. CSF samples were taken immediately before each intraspinal TCA application, to control the CSF for inflammatory reactions. 1 ml CSF was aliquoted and sampled in sterile Eppendorf tubes and stored at -70°C. Samples of these patients were analyzed using two different assays. In the first assay a very sensitive solid phase ELISA-type assay for detection of soluble RGMa in CSF samples was used. The second assay was an immunoblot analysis of CSF samples of TCA-treated progressive MS patients. As we used a selective polyclonal RGMa antibody, this assay detected all different forms of sRGMa in the samples. TCA application was followed by a mandatory stay in bed for at least six hours in order to support the diffusion of TCA in the cerebrospinal fluid and the spinal cord. Lumbar puncture was performed with an "atraumatic" Sprotte needle. The preexisting immune system modulating drug therapy remained stable. Spasticity reducing therapy, if administered, was not changed.
Statistics
Data analysis and statistical analysis was performed blinded using the GraphPad prism program. Repeated measures ANOVA was used to compare the significant differences between experimental groups to control groups.
